Syndax Pharmaceuticals Inc

Research Syndax Pharmaceuticals Inc (SNDX) on Bullrun: market cap USD 1.93B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerSNDX
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 1.93B
• Financial periodFY2025
• RevenueUSD 172.35M
• Revenue growth627.8%
• Net income-USD 285.40M
• Free cash flow-USD 323.17M

Valuation Snapshot

latest market cap is USD 1.93B.

About Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.

Frequently asked questions

What is Syndax Pharmaceuticals Inc's market cap?

Syndax Pharmaceuticals Inc's market capitalization is USD 1.93B.

What does Syndax Pharmaceuticals Inc do?

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia;